JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression

Oncogenic K‐RAS has been difficult to target and currently there is no K‐RAS‐based targeted therapy available for patients suffering from K‐RAS‐driven lung adenocarcinoma (AC). Alternatively, targeting K‐RAS‐downstream effectors, K‐RAS‐cooperating signaling pathways or cancer hallmarks, such as tumo...

Full description

Saved in:
Bibliographic Details
Published in:Int J Cancer
Main Authors: Mohrherr, Julian, Haber, Marcel, Breitenecker, Kristina, Aigner, Petra, Moritsch, Stefan, Voronin, Viktor, Eferl, Robert, Moriggl, Richard, Stoiber, Dagmar, Győrffy, Balázs, Brcic, Luka, László, Viktória, Döme, Balázs, Moldvay, Judit, Dezső, Katalin, Bilban, Martin, Popper, Helmut, Moll, Herwig P., Casanova, Emilio
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Inc. 2019
Subjects:
Cancer Therapy and Prevention
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6856680/
https://ncbi.nlm.nih.gov/pubmed/31407334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32624
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items